Agoracom Blog Home

Archive for the ‘All Recent Posts’ Category

SPONSOR: American Creek $AMK.ca – Billionaire Eric Sprott Dishes On His Golden Investment Spree: ‘It’s Like Being At A Table With A Winning Run’ $TUD.ca $SII.ca $GTT.ca $AFF.ca $SEA.ca $SA $PVG.ca $AOT.ca

Posted by AGORACOM at 3:03 PM on Wednesday, December 18th, 2019
  • Sprott is eager to believe junior gold miners are on the verge of striking the motherlode, but skeptical of nearly everything else related to the industry
https://financialpostcom.files.wordpress.com/2019/11/eric-sprott-1.jpg?quality=80&strip=all&w=780

One week before Halloween, Canada’s biggest gold enthusiast, the septuagenarian billionaire Eric Sprott, wearing a neatly pressed tuxedo, bounded onto a stage in a downtown Toronto ballroom and accepted his induction into Canada’s Investment Industry Hall of Fame.

He declared himself both humbled and honoured, and then rollicked into the wee hours of the night at his home in a nearby tower with expansive views of the city’s sparkling skyline. The next morning, though 75 and technically retired, he showed up at his office, grumbling about a lack of sleep, but dressed in a magenta-coloured, paisley button-up, ready for a 9 a.m. meeting with a penny stock exploration company.

“I keep reading that people are never making (gold) discoveries, the rate of discoveries is going down,” he said, occasionally rubbing his temples and closing his eyes. “The funny thing, well, I guess I’m the sucker then because I keep buying guys who say they’re making discoveries.”

Just as the price of gold often moves in the opposite direction of the stock market, Sprott has a strong contrarian streak that means he also often moves in the opposite direction of the market. For example, this past spring, after years of middling precious metal prices and declining discoveries had led most investors to abandon Canada’s gold and silver explorers, he decided to go all-in.

Sprott launched an investment blitz, the likes of which the junior mining precious metals sector had seldom seen, doling out somewhere between $200 and $300 million in a matter of just a few months to acquire large stakes in about two dozen companies, most of which have never earned a dollar of revenue

His investments between May and July accounted for about one in every four dollars raised by junior miners, according to Vancouver-based market research firm Oreninc. During that time, gold prices started to rise, breaking through US$1,400 in June for the first time in six years, bringing some investors back to the major miners — exactly where Sprott doesn’t want to be.

“They’re the worst place to put money, okay?” he said.

Putting his money where his mouth is, he has been selling his position in Kirkland Lake Gold Ltd., one of, if not the lowest-cost gold producers and one of the best-performing stocks on the S&P/TSX Composite Index since 2016.

Sprott was an early investor in Kirkland Lake, was appointed chairman in 2015, and one year later helped engineer its merger with Newmarket Gold Inc., a small gold producer in Australia. Not long after, the newly merged company discovered high-grade veins at two mines, which propelled its stock upwards to $63 per share.

Many investors pride themselves on not selling when a stock hits a bump, but Sprott said it is equally important to not sell when the stock rises, at least not until it’s gone up five or even 10 times, a so-called tenbagger.

“I’ve had lots of tenbaggers and the important thing is to stay in it,” he said.

But when his stake in Kirkland Lake reached about $1.3 billion earlier this year, and it looked like gold prices would keep rising, Sprott said he decided it was time to sell.

“Here’s what I say to the management of Kirkland Lake: you will not be the No. 1 performing stock this year,” he said during an interview in October. “You will not be, because companies like Eldorado (Gold Corp.) and Detour (Gold Corp.) are going to kick your butt.”

In November, Kirkland Lake announced it was buying Detour Gold Corp., and its stock fell by 15 per cent in a day, wiping out what he estimated to be around $140 million of his net worth.

And yet, Sprott — who found out about the deal on a day he was meeting with a junior mining company seeking investment — elected to support the deal, and waxes enthusiastic about Detour.

It’s one of the reasons why Sprott doesn’t much care about Canada’s major gold miners.

The best-run companies might provide 20- or 30-per-cent returns, or maybe 100 per cent in a few cases, but Sprott would rather invest in a company that might strike gold and give him a 500-per-cent return, or even a coveted 1,000-per-cent return.

Indeed, as merger activity heats up in the gold space, another one of Sprott’s investments, Continental Gold Inc., announced a $1.4-billion cash buyout at $5.50 per share.

In July, Sprott had bought about 10 million shares at $3.10, meaning he made about $25 million or a 75-per-cent return in just a few months. But he was nonplussed, saying the buyout may have come a little early.

“You’ve got to have the dream, right?” he said. “You’ve got to have the dream you’re going to find something.”

Therein lies Sprott’s biggest paradox: he’s eager to believe that junior gold miners are on the verge of striking the motherlode, but skeptical of nearly everything else related to the gold industry.

You’ve got to have the dream, right? You’ve got to have the dream you’re going to find somethingEric Sprott

After a five-decade career in the financial services industry, during which he worked as an investment banker and founded an eponymous empire that includes fund and asset management firms, a brokerage firm, bullion storage and more businesses, he is skeptical of commercial banks, major precious metals miners, central banks, the stated rate of annual inflation and, perhaps above all, gold and silver prices.

“One of the things about the media, they never talk about the gold conspiracy,” he said. “Look at the guys who are paying fines for spoofing the precious metals markets. Every two weeks some guy’s paying a fine.”

Case in point, U.S. prosecutors in September filed criminal charges against three JPMorgan Chase & Co. bankers for allegedly spoofing the precious metals market, which means placing fake orders and then quickly cancelling them to manipulate the price. The indictment alleged a decade-long conspiracy.

Sprott believes the futures market — where investors can buy options that essentially allow them to place bets on the price of gold or silver without actually having to own any of the metals — allows commercial banks to exert way too much influence on the market for physical metals.

Stacked gold bars in Germany.
Stacked gold bars in Germany. Michaela Handrek-Rehle/Bloomberg files

As someone who stockpiles bullion, and often gives it out as a gift, he watches the prices of silver and gold so closely it often colours his mood.

This fall, Sprott was out fishing for grouper on a staffed boat somewhere warm on a Friday when he normally records his podcast. In spite of his idyllic circumstances, he sounded distinctly downtrodden when he called in to the podcast.

“I’ve had better days, you know, it’s a bit of a tough one,” he said.

As the podcast progressed, it soon became clear that gold and silver prices were both down, about four and six per cent, respectively, and options market manipulation appeared to be the reason to him.

Juan Carlos Artega, director of investment research at the World Gold Council, is skeptical that banks are having a significant effect on gold or silver prices through the futures market, but believes options do have an impact on short-term prices.

As someone who stockpiles bullion, and often gives it out as a gift, he watches the prices of silver and gold so closely it often colours his mood

“What you find is that the gold price is responding to demand-and-supply dynamics including those on the (options) market, but it’s only one component,” he said.

Artega said central bank and consumer buying, production numbers, recycling, investment in gold-backed exchange-traded funds and a host of other factors play a role in determining long-term prices.

Sprott would hear none of it, and said he’s long disagreed with the World Gold Council about many things. His skepticism of the futures market ties in to his skepticism of the financial market writ large.

“We have a weird financial system; it doesn’t make any sense to a rational thinker,” he said.

Gene McBurney, co-founder of GMP Securities LP, once a competitor of Sprott Inc. in the investment business and now a friend, said part of the key to understanding Sprott is that he enjoys entertaining other people with provocative comments.

Fine gold coins at a bullion dealer in London.
Fine gold coins at a bullion dealer in London. Chris Ratcliffe/Bloomberg files

“He’s told people there’s no gold in Fort Knox; that kicks off an interesting conversation,” he said.

But McBurney added that he believes Sprott is extremely well versed in the companies in which he invests, and he has even given some of his personal money to Sprott to manage.

Peter Grosskopf, chief executive of Sprott Inc., the asset management firm Sprott founded and a mentee, said Sprott is always covered as being this “unbelievable gold bug,” but there’s a lot more to it than that.

“I mean, he’s a savant at what he does,” said Grosskopf, who added that it’s not easy to explain how Sprott does what he does.

That’s mainly because Sprott is investing in companies that have no revenue, which means standard investment metrics, such as internal rate of return, aren’t necessarily useful, never mind that he said they’re not something he would use.

He’s a savant at what he doesPeter Grosskopf, chief executive of Sprott Inc.

Instead, he attempts to value companies based on whether they are likely to discover a deposit of precious metals.

Of course, even if a company discovers a deposit, it would still need to figure out whether it makes economic sense to extract the deposit, including how much it would cost to build and operate a mine, which requires further calculations about energy costs, transportation, processing and refining, and so on.

Sprott said he focuses solely on the deposit and how big it could be. Though he has no education in geology, he said he has devised his own valuation method, which involves looking at a few variables to determine the potential size of a deposit.

“I want to turn it into numbers, like, okay, what could this thing earn?” he said. “You know, you multiply the strike by the depth by the width by 2.7 specific gravity times the ounces — it’s just four or five things you’ve got to multiply, five things.”

People close to him said he studies junior mining companies and can recall the details of his investments better than most fund managers.

“The guy gets up at ungodly hours, he might get up at 2 a.m. studying,” said Conor O’Brien, a former capital markets manager who joined Sprott in May to help with the investment blitz. “Neither one of us are geologists, we’re just financial people that can do mathematics, as opposed to the geology. We more kind of conceptualize, and dream and kind of multiply.”

Putting his latest investment spree of more than $200 million in perspective, the TSX Venture Exchange’s junior mining sector through August was on course to raise $2 billion for all of 2019, about 27 per cent less than it did in 2009.

Sprott takes a birdshot approach to investment that spreads his money far and wide, so that his portfolio contains companies exploring for high-grade and low-grade mines, potential open-pit and potential underground mines, and so on.

“Most of them won’t make it,” he said. “But what about the ones that do? If I’m in early and I stay the ground, I press the bet. It’s like being at a table with a winning run, you keep doubling down.”

Grosskopf said Sprott calls it “stealing value,” not because he’s conning anyone, but because he’s investing in assets the market has mispriced. He said the billionaire is an expert trader, adept at sizing up an opportunity and timing his entrance and exit.

And because of his outsized profile, recently juiced by his epic returns while chairman of Kirkland Lake, there are hordes of investors who will follow his lead, Grosskopf said.

Not all of Sprott’s bets work out, of course. In 2017, Sprott said he invested in Garibaldi Resources Corp., a nickel explorer, based on comments he read on an online chat board.

Its stock surged 1,731 per cent that year, and Sprott has continued to invest even though two years later, its stock has declined from a peak above $4 in late 2017 to 87 cents today.

“They’re for sure drilling, we know that, and they’ve announced some holes, and they’ve got more to go,” Sprott said. “They haven’t found the motherlode they’re looking for. Even I’ll say that.”

Sprott’s vast ownership may also have a downside: It’s not easy to liquidate his positions in companies without attracting attention. But his vast wealth also means he’s relatively insulated from a lot of threats, such as dilutive financings or litigation, that smaller investors can’t afford to participate in.

He also owns a private gold mining company in Nevada called Jerritt Canyon Gold LLC, which he said made its first profit in the third quarter.

Kevin Small, vice-president of operations at that mine, said Sprott likes to be generous. In April, he said Sprott showed up at the site and handed out silver coins to several hundred people who work there.

“He said when you guys make lots of money, I’ll give you each a gold coin, but he hasn’t been back yet,” Small said.

Eric Sprott at his induction into Canada’s Investment Industry Hall of Fame in October.
Eric Sprott at his induction into Canada’s Investment Industry Hall of Fame in October. Peter J. Thompson/National Post

But he added that Sprott has been investing heavily in the operation, which has a capacity to produce 280,000 ounces of gold per year, and predicted the company would soon be well known.

Colleagues also add that he can be unrelenting when judging a company’s financial performance. Case in point, one of his biggest gripes with Kirkland Lake is that he wants it to increase its dividend, an issue he once again raised in October after the miner posted solid quarterly results.

Kirkland Lake pays a quarterly dividend of four cents, and chief executive Tony Makuch said he may consider raising it, but the company still needs to spend money on exploration so it can improve its reserves of gold.

“We’re not an industry people should be buying for dividends,” Makuch said. “You should be buying bank stocks or something else. If you look at our share price, that comes from investing in new projects.”

It’s a sentiment that Sprott would likely agree with.

“I still have a lot of money in Kirkland and it’s a great company, but it’s not a tenbagger from here,” he said. “And I like tenbaggers as opposed to 100 per cent. It’s just my nature.”

SOURCE: https://business.financialpost.com/commodities/mining/billionaire-eric-sprott-dishes-on-his-golden-investment-spree-its-like-being-at-a-table-with-a-winning-run

CLIENT FEATURE: Gratomic $GRAT.ca – Creating the Graphene Tire Market $GRAT.ca $SRG.ca $NGC.ca $LLG.ca $GPH.ca $NOU.ca

Posted by AGORACOM at 2:47 PM on Wednesday, December 18th, 2019
  • The global tire market acknowledges that employing graphenes within tire treads, walls and the inner linings can make tires lighter, provide better grip and reduce rolling resistance to an extent that is not possible with existing tire compounds
  • Key to the ability for Gratomic to establish the first mass-market Mine to Graphene to Tire, is the production of large quantities of graphenes nano surface modified to enhance tire performance
  • Gratomic is developing and commercializing its Graphene Processing capacity in Wales through its partnership with Perpetuus carbon technologies and prepared an additional 2 tonnes of Graphite concentrate for converting into high quality Graphenes targeted for the use and development of several high value Graphene applications.

Tire Outperformance Categories:

 Rolling resistance

 Braking/grip on wet and ice roads

 Abrasion resistance

Tires, enhanced with surface engineered graphenes, produced a greater than 30% increase in wear resistance over the competing Brand Tires, equating to an additional +30% mileage before the tire was needed to be replaced.

Furthermore, the results of testing carried out by industry experts employing industry standard dynamic mechanical analysis (DMA) showed a significant improvement in rolling resistance, which indicated a greater than 30% improvement in fuel economy (increased MPG).

Results showed a greater than a 40% improvement in both wet and ice braking.

About Gratomic Inc.

Gratomic is an advanced material company focused on mine to market commercialization of graphite products, most notably high-value graphene-based components for a range of mass market products.

Gratomic Hub on Agoracom

FULL DISCLOSURE: Gratomic is an advertising client of AGORA Internet Relations Corp.

CardioComm Solutions $EKG.ca – Remote Patient Monitoring, Reimbursement Topped Headlines in 2019 #Mhealth $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 1:39 PM on Wednesday, December 18th, 2019

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

Remote Patient Monitoring, Reimbursement Topped Headlines in 2019

Top mHealth trends in 2019 included remote patient monitoring, telehealth reimbursement, substance use disorder care, chronic disease management, and direct-to-consumer mHealth technology.

  • Based on our most clicked stories in 2019, those trends included remote patient monitoring, telehealth reimbursement and coding, behavioral health/substance use disorder care, chronic disease management strategies, and direct-to-consumer mHealth technologies.

By Samantha McGrail

As 2019 comes to an end, healthcare organizations are reflecting on the trends and stories that most influenced their behaviors in the past year. Based on our most clicked stories in 2019, those trends included remote patient monitoring, telehealth reimbursement and coding, behavioral health/substance use disorder care, chronic disease management strategies, and direct-to-consumer mHealth technologies.

In the following article, mHealthIntelligence.com will break down these trends, as well as the strategies and best practices industry leaders developed in response. 

Remote patient monitoring

In 2019, healthcare organizations looked to invest in remote patient monitoring (RPM) solutions to transition to value-based care. Many healthcare leaders expected these solutions to support high-risk chronically ill patients whose conditions are considered unstable and at a risk for hospital admission. 

Specifically, 88 percent of providers who were surveyed by health IT thought leaders earlier this year had invested or were evaluating investments in RPM technologies. 

RPM solutions have been proven to be clinically effective as an early symptom management tool for chronically ill patients, who represented about 45 percent of the US population according to the survey. These solutions allowed risk-bearing organizations to remotely monitor patients with chronic conditions to help control healthcare costs, improve care quality, and increase access to care for patients in underserved areas. 

In addition, these solutions helped manage value-based risk associated with large patient populations with chronic conditions. 

“The ability of the device to simultaneously record multiple variables such as heart rate and accelerometer data allowed us to more accurately determine the patient’s state, whether he/ she is active, sedentary, asleep, or not currently using the device,” the researchers reported.

Because remote patient monitoring is becoming more widespread, more healthcare organizations are implementing RPM into their health systems. Recently, Humana announced a partnership with Philips Health to launch a remote member monitoring pilot for certain Medicare Advantage members with severe congestive heart failure (CHF).

“Our goal is to continue to find ways to help our Medicare Advantage members stay longer and safer in their homes,” Susan Diamond, president of Humana’s Home Business segment, said in a press release.

Telehealth reimbursement and coding

Along with remote patient monitoring, telehealth has been extremely vital for healthcare in 2018 and will continue to play a significant role going into the new year. But healthcare organizations are still waiting on reimbursement and billing policies to catch up to telehealth adoption..

One of the top read stories from 2019 was the American Medical Association’s (AMA) creation of new codes for the use of telehealth and behavior assessment and intervention services. These codes “more accurately reflect current clinical practice that increasingly emphasizes interdisciplinary care coordination and teamwork with physicians in a primary care and specialty setting,” the association stressed. 

The goal for the new codes was to expand pathways for physicians across the US who deal with diverse patients, including those from underserved areas, and those who have any access to care they may need. 

CMS has followed suit, implementing the AMA and its Digital Medicine Payment Advisory Group to include new telehealth codes in the 2018 Medicare physician fee schedule. And in the beginning of this year, CMS released its 2020 physician fee schedule that included numerous additions that will enable more reimbursement for connected health services next year. 

In October of this year, Pennsylvania tried again to pass comprehensive telehealth legislation after the bill was denied last year because of disagreements over payment parity. 

State Senator Elder Vogel introduced The Telemedicine Act (SB 857), which aimed to establish definitions for telemedicine and telehealth, provide temporary evaluation and treatment guidelines for reimbursement, and give state departments up to two years to draft permanent rules and regulations. 

The new bill includes remote patient monitoring technologies, which gives providers the opportunity to use these connected health services. About a dozen states have passed legislation demanding payment parity for telehealth, but most have failed because of strong opposition from healthcare payers. 

Addressing substance abuse using mHealth

An estimated 115 people die each day from opioid abuse, an issue that has become more widespread in the past decade. Healthcare providers have been actively searching for a solution to tackle this issue, and many have found a pathway to success using mHealth and telehealth technology.

Applying MHealth and telehealth technology to addiction treatment is expected to make one of the biggest impacts on substance use disorder care. Connected health platforms allow providers to work with the individual patient anytime they need to, and are able to see what the patient experiences each day. 

“We’re building a panoramic view of your life,” said Jacob Levenson, CEO of MAP Health Management, a Texas-based national network of almost 100 addiction treatment providers. The organization has adopted digital health tools for care management and coordination of substance use disorder patients.

The smartphone is also a great tool for addiction treatment, as it offers both a platform for population health programs and individual treatments. Healthcare providers are able to send out messages offering support or information via text, SMS, or e-mail to large groups at any time. They can also personalize messages for individuals, connecting information to one’s habits, location, or medical record.

MHealth apps are becoming increasingly more popular tools. Apps could feature surveys, messaging or chat rooms, links to resources, messaging with care providers or a substance abuse specialist, and a 911 link for immediate help. 

“Medical devices, including digital health devices like mobile medical apps, have the potential to play a unique and important role in tackling the opioid crisis,” FDA Commissioner Scott Gottlieb, MD, said in a press release featured on the FDA website. “We must advance new ways to find tools to help address the human and financial toll of opioid addiction.” 

Chronic disease management strategies

While MHealth platforms were important for addressing the opioid crisis, the solutions have also been useful for chronic disease management. A growing number of Americans are suffering from more than one chronic condition, prompting more healthcare providers to take the appropriate measures to tackle this issue in 2019.

For example, in January, Omada Health, a digital therapeutics company that focuses on obesity-related chronic conditions, created a cognitive behavioral therapy program (CBT) for those dealing with depression and anxiety. 

“Depression and anxiety are a known barrier to healthy behaviors including medication adherence, optimal nutrition, and seeking timely preventive care. With the addition of CBT curriculum, we can more fully support our participants as they manage their conditions. And, through our digital platform, we can do it at scale,” Carolyn Bradner Jasik, MD, Omada’s Vice President of Medical Affairs, explained in a press release.

The challenge going into the coming years is developing a digital health platform that is able to integrate different programs and allow for easy access for both patients and providers.

A few weeks ago, a Pennsylvania health system also created a telehealth and remote patient monitoring platform to allow patients living with ALS to receive at home care. Most patients with ALS have to travel hours for meetings with doctors and specialists, which can prove to be challenging. But the telehealth platform allows the meetings to be held at home. 

Heart failure (HF) patients receiving targeted virtual behavior therapy found significant improvements in self-care, a recent study published in the journal Circulation found. The study conducted by Humana and AbleTo found a correlation between improving behavioral health care and co-existing physical conditions. The study also noted improvements in self-care, depression symptoms, and awareness of physician recommendations among patients that received HF-focused virtual behavioral therapy over eight weeks.

Chronic disease management is vital to reduce costs by addressing the patient’s illness or condition with maximum clinical outcomes, while helping beneficiaries control their disease in an effective way. 

Direct-to-consumer mHealth technology

The healthcare industry is facing major disruption from non-traditional companies, like Amazon, Google, and Apple. The mHealth space has been no different according to the top stories from 2019.

In September of this year, Amazon prepared to take on the direct-to-consumer telehealth industry through its new platform, Amazon Care. Amazon Care is a virtual care clinic offering telehealth and mHealth services for its employees in the Seattle area, including on-demand access to a clinician online messaging for healthcare questions, a prescription service, and the option of scheduling an appointment through Seattle-based Oasis Medical. 

Apple Watch can be used by clinicians to detect atrial fibrillation. But will care providers rely on these devices to present them with accurate information?

A survey of 420,000 individuals conducted by researchers at the Stanford University School of Medicine found that over an eight month span, the Apple Watch detected an irregular heart rate in .52 percent of individuals or 2,161 people. And almost three-quarters of the users who were notified about an irregular pulse contacted a care provider for further treatment.

“The study’s findings will help patients and clinicians understand how devices like Apple Watch can play a role in identifying atrial fibrillation, a deadly and often undiagnosed disease,” Mintu Turakhia, MD, an associate professor of cardiovascular medicine, said in the press release. “Additionally, these important findings lay the foundation for further research into the use of emerging wearable technologies in clinical practice and demonstrate the unique potential of large-scale app-based studies.”

In addition, a Gallup survey this month showed that nearly one in five Americans are using an mHealth wearable. Adults younger than 55 are twice as likely to use or have used mHealth. And individuals older than 55 and women, are more interested in using mHealth than men. About half of the women respondents under 55 said they use or have used mHealth in the past. While men over age 55 are the least likely to use or have used the technology.

Jefferson Health recently partnered with Quick’r Care to create a mHealth platform to allow patients to choose their correct care path. Through JeffConnect’s virtual care service. Consumers will have on-demand video access to health system’s care providers.

“This is what people who feel bad need right now, right when they begin to feel sick,” added Stephen K. Klasko, MD, president of Thomas Jefferson University and CEO of Jefferson Health. “Working with Quick’rCare allows us to expand our commitment to healthcare with no address.”

Overall, Apple products are designed to make healthcare more human. Devices are meant to protect patient data and give easy accessibility to everyone who uses Apple products. Patients are able to access medical records and communicate from at home if needed. But providers continue to question whether the information they are receiving is accurate, as with new technologies, there isn’t always this guarantee.

Source: https://mhealthintelligence.com/news/remote-patient-monitoring-reimbursement-topped-headlines-in-2019

SPONSOR: Affinity Metals $AAF.ca – Central Banks’ Appetite For Gold Expected To Continue $SII.ca $TUD.ca $GTT.ca $AMK.ca $OSK.ca

Posted by AGORACOM at 11:45 AM on Wednesday, December 18th, 2019

Sponsor: Affinity Metals (TSX-V: AFF) a Canadian mineral exploration company building a strong portfolio of mineral projects in North America. The Corporation’s flagship property is the Drill ready Regal Property near Revelstoke, BC. Recent sampling encountered bonanza grade silver, zinc, and lead with many samples reaching assay over-limits. Further assaying of over-limits has been initiated, results will be reported once received. Click Here for More Info

Central bankers have been voracious buyers of gold during the last two years, and analysts look for that trend to continue in 2020.

Through the end of October, net official-sector purchases this year totaled 562 metric tons, reported Alistair Hewitt, director of market intelligence with the World Gold Council. That 56.2-tons-a-month average puts sales on pace to roughly match the 656 tons bought in 2018, which were the most central-bank purchases since 1967, according to WGC data.

“This year has been exceptionally strong. We think that next year, net buying will continue at a high level, even if it’s not as high as this year,” said Philip Newman, director of the London-based consultancy Metals Focus.

Goldman Sachs looks for global central banks to collectively acquire around 650 tons in 2020, while Standard Chartered is projecting central-bank purchases will total 525 tons.

“It’s still elevated,” said Suki Cooper, precious-metals analyst with Standard Chartered. “That is still firmly on the buy side.”

‘Safe, liquid and generates returns’

Hewitt commented that central banks are looking at three main criteria when deciding to expand the amount of gold they hold within their foreign-exchange reserves.

“For a central bank, gold is a fantastic asset because it’s safe, liquid and generates returns over the long term,” Hewitt said.

He also listed two more factors why the central-bank buying has suddenly jumped in recent years.

“One issue is we are seeing heightened geopolitical tensions,” Hewitt said, with these involving major gold-buying countries and economies. “Central banks are looking toward gold to balance some of that risk.

“We’ve also got negative rates and yields for a large number of sovereign bonds.”

Newman added that many central banks are “trying to get away” from the U.S. dollar. This is especially the case with Russia due to U.S. sanctions, he added.

As recently as 2017, most of the official-sector buying came from a handful of central banks, including Russia, Turkey and Kazakhstan. But in 2018 and 2019, there have been a slew, including some that had not been in the market for years.

“You’ve got a whole range of buyers,” Newman said.

The largest buyers during the first 10 months of the year were Turkey with 144.8 tons; Russia, 139; Poland, 100; and China, 95.8.

Others include Kazakhstan, 26.9 tons; India, 17.7; Qatar, 11; Ecuador, 10.6; Serbia and the U.K., 9.9; Argentina, 7; Colombia, 6.1; Kyrgyz Republic, 3.2; Mongolia, 2.3; Belarus, 1.9; Guinea, 0.9; Egypt and Mauritania, 0.7; Albania and Malta, 0.6; and Ukraine and Greece, 0.3.

Goldman Sachs projected that central-bank purchases could amount to as much as 22% of global supplies during 2019.

Central banks ‘buy for an extended period’

Hewitt looks for official-sector buying momentum to continue.

Central banks tend to put a lot of thought into decisions to buy – with a long, rigorous policy-making process — and purchase the metal for strategic reasons, rather than simply reacting to day-to-day moves in the price, Hewitt said.

“Once these people start buying, they continue to buy for an extended period of time,” Hewitt said. For instance, he pointed out that Kazakhstan has been a regular gold buyer since 2010.

“Both trade tensions and negative yields are still here,” Hewitt said. “They may rear their ugly heads again and become more pronounced, or they may fade away and become less pronounced. But those underlying forces will remain ever present in the market. Certainly in the next year or so, those two factors should continue to support and underpin central-bank demand for gold.”

Observers pointed out that not only have central-bank gold purchases been strong, but sales have been light. Back in 1999, when European central banks were selling the metal, they began following central-bank sales agreements to try to limit how much was sold in any one year and thereby keep this from being a destabilizing force in the gold market.

These agreements have been discontinued, Hewitt noted. Commerzbank analysts pointed out they were no longer necessary since hardly any European central banks are selling anyway. Germany’s central bank sells a modest amount each year only for its coin-minting program, Hewitt said.

“The market was not bothered by the central-bank gold agreement coming to an end, partly because the gold market is very different from what it was in 1999,” Hewitt said, adding that there “dramatic selling” back then.

“The gold market today is just more diverse, more resilient and more liquid. That’s why the market just shrugged its shoulder when the central-bank gold agreement came to an end.”

Further, analysts at Commerzbank, in their 2020 outlook, commented that one or more Western European central banks might even enter the market as a gold buyer.

“One possible candidate is the Dutch central bank (DNB), which in October published a remarkable statement about the role of gold on its website,” Commerzbank said. “In it, it described gold as an anchor of trust for the financial system. According to the DNB, gold reserves could serve as the basis for a new beginning in the event of a system collapse.

“If one or more Western central banks indeed started to actively buy gold, this would attract considerable attention and spark market reactions.”

SOURCE: https://www.kitco.com/news/2019-12-18/Central-banks-appetite-for-gold-expected-to-continue.html

Applied BioSciences $APPB Subsidiary, Trace Analytics, Receives Extension of Contract of Services from Washington State Department of Agriculture $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 8:37 AM on Wednesday, December 18th, 2019
  • Trace Analytics Inc. is a leading scalable analytics cannabis/cannabinoid laboratory poised to meet the demands for mandated regulatory cannabis/cannabinoid testing
  • WSDA contracted Trace Analytics for the purpose of doing cannabinoid profiling for the State’s industrial hemp program to ensure the percentages of certain cannabinoids are below Federal limits

Applied BioSciences Corp. (OTCQB:APPB) (“Applied” or the “Company”), today announced that the Washington State Department of Agriculture (WSDA) has extended its contract for services with Applied’s majority owned subsidiary, Trace Analytics Inc. (“Trace”).

The WSDA contracted Trace beginning in July 2019 for the testing of Industrial Hemp samples and percentage testing for delta 9-tetrahydrocannabidiol (THC) and delta 9-tetrahydocannabinolic acid (THC-A) to ensure the percentages of certain cannabinoids are below Federal limits.

“We are grateful for our relationship with the WSDA and are pleased to continue cannabinoid profiling for the WSDA’s Industrial Hemp program. The testing and reporting of results that we have conducted to date have demonstrated the quality of our analytics and our dedication to ensuring compliance with Federal limits,” stated Jason Zitzer, Chief Operating Officer of Trace Analytics. “We provide expert consulting services to government entities at all levels around the world and are appreciative to WSDA to have been selected as the sole lab to conduct their testing. This contract extension provides another opportunity toward establishing a higher quality for cannabis and hemp testing.”

Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology, focused on ensuring compliance with public safety standards and end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally with the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing. The Company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world.

Based on Applied BioSciences’ stated strategic corporate shift to focus on its BioPharma division and the development and commercialization of novel therapeutics that target the endocannabinoid system (ECS), the Company is currently evaluating a strategic transaction of Trace Analytics. Applied is currently in late-stage discussions and expects to close the transaction by year end.

About Applied BioSciences Corp.

Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. We also deliver high-quality consumer and OTC THC-free CBD products that promote overall health and wellbeing as well as state-of-the-art testing and analytics capabilities to our customers. For more information, visit appliedbiocorp.com and connect with the Company on Twitter, Facebook and LinkedIn.

Applied BioSciences $APPB: What Is the Endocannabinoid System And What Is Its Role? $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 4:06 PM on Tuesday, December 17th, 2019

SPONSOR: Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas Click Here for More Info

Some of us consume cannabis for its mind-altering effects, while others seek symptom relief. But cannabis wouldn’t get us high or have some of its therapeutic benefits if our bodies didn’t already contain a biological system capable of interacting with its active chemical compounds, like THC.

Our endocannabinoid system does just that. But it isn’t there just to allow us to enjoy the effects of our favorite strain. It serves a vital purpose for our health and well-being because it regulates key aspects of our biology. So, what’s it doing, and how does it work?

Homeostasis: Staying in the Goldilocks zone

rocks on a beach

To understand the human endocannabinoid system, it’s helpful to know a little about one of the most fundamental concepts in biology: homeostasis. And the best way to understand homeostasis is to think of Goldilocks and the three bears.

That classic fairy tale illustrated the idea that the best outcome often lies somewhere in the middle, between two extremes. We don’t want things too hot or too cold, but just right.

Homeostasis is the concept that most biological systems are actively regulated to maintain conditions within a narrow range. Our body doesn’t want its temperature to be too hot or too cold, blood sugar levels too high or too low, and so on. Conditions need to be just right for our cells to maintain optimum performance, and exquisite mechanisms have evolved to draw them back to the Goldilocks zone if they move out. The body’s endocannabinoid system (ECS) is a vital molecular system for helping maintain homeostasis—it helps cells stay in their Goldilocks zone.

Key pieces of the endocannabinoid system (ECS)

Because of its crucial role in homeostasis, the ECS is widespread throughout the animal kingdom. Its key pieces evolved a long time ago, and the ECS can be found in all vertebrate species.

The three key components of the ECS are:

  • Cannabinoid receptors found on the surface of cells
  • Endocannabinoids, small molecules that activate cannabinoid receptors
  • Metabolic enzymes that break down endocannabinoids after they are used

Cannabinoid receptors

Cannabinoid receptors sit on the surface of cells and “listen” to conditions outside the cell. They transmit information about changing conditions to the inside of the cell, kick-starting the appropriate cellular response.

There are two major cannabinoid receptors: CB1 and CB2. These aren’t the only cannabinoid receptors, but they were the first ones discovered and remain the best-studied. CB1 receptors are one of the most abundant receptor types in the brain. These are the receptors that interact with THC to get people high. CB2 receptors are more abundant outside of the nervous system, in places like the immune system. However, both receptors can be found throughout the body (Figure 1).

endocannabinoid system cannabinoid receptors CB1 and CB2 in the body

Figure 1: Where are CB1 and CB2 receptors located in the body?
The CB1 and CB2 receptors are key players in the endocannabinoid system (ECS). They are located on the surface of many different types of cells in the body. Both receptors are found throughout the body, but CB1 receptors are more abundant in the central nervous system, including on neurons in the brain. In contrast, CB2 receptors are more abundant outside of the nervous system, including cells of the immune system.

Endocannabinoids

Endocannabinoids are molecules that, like the plant cannabinoid THC, bind to and activate cannabinoid receptors. However, unlike THC, endocannabinoids are produced naturally by cells in the human body (“endo” means “within,” as in within the body).

There are two major endocannabinoids: anandamide and 2-AG (Figure 2). These endocannabinoids are made from fat-like molecules within cell membranes, and are synthesized on-demand. This means that they get made and used exactly when they’re needed, rather than packaged and stored for later use like many other biological molecules.

Anandamide and 2-AG are the two major endocannabinoids produced naturally in the body

Figure 2: Anandamide and 2-AG are the two major endocannabinoids.
Cannabinoids are a class of molecules characterized by their ability to activate cannabinoid receptors like CB1 and CB2. Anandamide and 2-AG are the two major endocannabinoids produced naturally in the body. THC is the psychoactive plant cannabinoid produced by Cannabis. All three of these cannabinoids can activate the CB1 and CB2 receptors, although each one has a different potency at each receptor.

Metabolic enzymes

The third piece of the endocannabinoid triad includes the metabolic enzymes that quickly destroy endocannabinoids once they are used. The two big enzymes are FAAH, which breaks down anandamide, and MAGL, which breaks down 2-AG (Figure 3). These enzymes ensure that endocannabinoids get used when they’re needed, but not for longer than necessary. This distinguishes endocannabinoids from many other molecular signals in the body, such as hormones or classical neurotransmitters, which can persist for many seconds or minutes, or get packaged and stored for later use.

FAAH and MAGL are the key enzymes of the endocannabinoid system

Figure 3: FAAH and MAGL are the key enzymes of the endocannabinoid system.
Enzymes are molecules that accelerate chemical reactions in the body, often for breaking down molecules. FAAH and MAGL are key players in the ECS because they quickly break down endocannabinoids. FAAH breaks down anandamide, while MAGL breaks down 2-AG. These enzymes break down endocannabinoids very quickly, but are not effective at breaking down plant cannabinoids like THC.

The three key components of the ECS can be found within almost every major system of the body. When something brings a cell out of its Goldilocks zone, these three pillars of the ECS are often called upon to bring things back, thus maintaining homeostasis. Because of its role in helping bring things back to their physiological Goldilocks zone, the ECS is often engaged only when and where it’s needed. Dr. Vincenzo Di Marzo, Research Director at the Institute of Biomolecular Chemistry in Italy, put it to us this way:

“With the ‘pro-homeostatic action of the ECS’ we mean that this system of chemical signals gets temporarily activated following deviations from cellular homeostasis. When such deviations are non-physiological, the temporarily activated ECS attempts, in a space- and time-selective manner, to restore the previous physiological situation (homeostasis).”

In other words, the ECS helps bring things back to the biological Goldilocks zone.

Below we will consider examples of how the ECS helps maintain homeostasis in two areas: the firing of brain cells in the nervous system, and the inflammatory response of the immune system.

Endocannabinoid regulation of brain cell firing

Brain cells (neurons) communicate by sending electrochemical signals to each another. Each neuron must listen to its partners to decide whether it will fire off its own signal at any given moment. However, neurons don’t like to get too much input—there’s a Goldilocks zone. If they get overloaded by signals, it can be toxic. That’s where endocannabinoids come in.RelatedHow Does Cannabis Consumption Affect the Brain?

Consider a simplified scenario with one neuron listening to two others. One of these two neurons might become overactive and send too many signals to the neuron that’s listening. When that happens, the neuron that’s listening will make endocannabinoids specifically where it’s connected to the overactive neuron. Those endocannabinoids will travel back to the “loud” neuron where they bind to CB1 receptors, transmitting a signal that instructs it to quiet down. This brings things back to the Goldilocks zone, maintaining homeostasis (Figure 4).

endocannabinoid system regulation of brain cell firing

Figure 3: Endocannabinoid signals regulate how active our brain cells are.
Under normal circumstances (top-left), a given brain cell (neuron) will get just the right amount of input from its partners—not too much, not too little. However, some of its partners can become overactive, and send an excessive number of signals (top-right). The neuron that’s listening will detect this, and release endocannabinoids that tell the other neuron to quiet down (bottom). This kind of mechanism helps maintain homeostasis because it helps prevent neurons from sending out too many signals.

As the example above illustrates, endocannabinoids travel backwards, which is why they’re known as retrograde signals. Most of the time, information flow between neurons is strictly in one direction, from “sender” neurons that release neurotransmitter signals to “receiver” neurons that listen to those signals. Endocannabinoids allow receiver neurons to regulate how much input they’re getting, and they do this by sending retrograde signals (endocannabinoids) back to overactive sender neurons.

But the brain isn’t the only organ that needs to maintain homeostasis. Every other system of the body, from the digestive to the immune system, needs to carefully regulate how its cells are functioning. Proper regulation is crucial for ensuring survival.

Endocannabinoid regulation of inflammation

Inflammation is a natural protective reaction the immune system has in response to infection or physical damage. The purpose of inflammation is to remove pathogens (germs) or damaged tissue. The inflamed area is produced by fluid and immune cells moving into the area to do the dirty work and return things to their Goldilocks zone.

It’s important that inflammation be limited to the location of damage and doesn’t persist longer than needed, which can cause harm. Chronic inflammation and auto-immune diseases are examples of the immune system getting activated inappropriately. When that happens, the inflammatory response lasts too long (which results in chronic inflammation) or gets directed toward healthy cells (which is known as auto-immunity).RelatedCannabis and Arthritis

In general, endocannabinoids seem to suppress or limit the immune system’s inflammatory signals. Professor Prakash Nagarkatti, Vice President for Research at the University of South Carolina whose laboratory studies endocannabinoid regulation of immune responses, told us how tweaking the ECS might be a good way to treat inflammatory diseases.

“Most of our research demonstrates that endocannabinoids are produced upon activation of immune cells and may help regulate the immune response by acting as anti-inflammatory agents. Thus, interventions that manipulate the metabolism or production of endocannabinoids may serve as a novel treatment modality against a wide range of inflammatory disease.”

Consider a normal immune response triggered by a bacterial infection. First, immune cells detect the presence of bacteria and release pro-inflammatory molecules that tell other immune cells to come and join the fight. Endocannabinoids get released as well (Figure 4), which also signal to other immune cells for assistance and likely help limit the inflammatory response so it isn’t excessive. By tightly regulating inflammation, the immune system can destroy germs or remove damaged tissue, and then stop. This prevents excessive inflammation, allowing cells, and thus the body, to return to the Goldilocks zone.

the endocannabinoid system and inflammation

Figure 4: Endocannabinoids help regulate inflammation.
Under normal conditions (top-left), cells of the immune system patrol the body, on alert for any intruders, such as bacteria. During a bacterial infection (top-right), immune cells detect the presence of bacteria and then release a variety of molecules to help mount a defensive attack (bottom). These signals include pro-inflammatory molecules (small circles) that help recruit more immune cells to the site of infection. Endocannabinoids (small diamonds) also get released, and likely help regulate the magnitude and extent of this inflammatory response.

How do plant cannabinoids like THC and CBD interact with the endocannabinoid system?

The reason that plant cannabinoids have psychoactive and medicinal effects within the body is, in large part, because we have an endocannabinoid system (ECS) that they can interact with. For example, THC gets you high because it activates the CB1 receptor within the brain. Endocannabinoids like anandamide also activate CB1.

So why aren’t we constantly high?

A couple big reasons. First, THC doesn’t interact with CB1 receptors in exactly the same fashion as the body’s natural endocannabinoids. Second, the metabolic enzymes that quickly break down endocannabinoids like anandamide don’t work on THC, so THC lingers around for much longer.

It’s important to remember that molecules like cannabinoids and other neurotransmitters rarely interact with only one receptor type; they often interact with many. The plant-based cannabinoid CBD illustrates this nicely, as it interacts with numerous receptor types in the brain. So, while plant cannabinoids may activate the same cannabinoid receptors as endocannabinoids, they will likely interact with several other receptors and therefore have distinct effects.

CBD is also interesting because it can affect overall levels of endocannabinoids in the brain, referred to as “endocannabinoid tone.” CBD inhibits the FAAH enzyme, which breaks down anandamide. Thus, CBD can increase anandamide levels by preventing FAAH from breaking it down. Inhibiting the FAAH enzyme has been shown to be a useful strategy for treating anxiety disorders, and some of CBD’s anti-anxiety properties may come from its ability to inhibit this enzyme and thereby increase endocannabinoid tone.

Summary

The endocannabinoid system (ECS), comprised of cannabinoid receptors, endocannabinoid molecules, and their metabolic enzymes, is a crucial molecular system that the body uses to help maintain homeostasis. Because of its vital role in making sure that cells and systems remain in their physiological Goldilocks zone, the ECS is tightly regulated; it gets deployed exactly when and where it’s needed. However, this doesn’t mean that activating the ECS, through consumption of cannabis or by any other means, will always make things just right.

Like any other complex biological system, the ECS can go awry. “If deviation from physiological homeostasis is prolonged, due to either external factors or chronic pathological conditions, the eCS can lose its time- and space-selective mode of action and start affecting inappropriate cells,” Dr. Di Marzo explained. “In these cases, the ECS, instead of being beneficial, may actually contribute to disease progression.”

It’s important to remember that activating the ECS, through cannabis consumption or by any other means, isn’t a cure-all. Like most of biology, it’s complicated.

By understanding the biological Goldilocks principle (homeostasis), and how the ECS illustrates this at the cellular level, we can more deeply appreciate why we have an ECS to begin with, and how a variety of cannabis-based therapies might actually work. The presence and critical function of the ECS across many systems of the body, including the nervous and immune systems, explains why such a wide variety of ailments and disease states are responsive to cannabis-based interventions.


References
Gunduz-cinar O, Hill MN, Mcewen BS, Holmes A. Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci. 2013;34(11):637-44. [PDF]
Ligresti A, De petrocellis L, Di marzo V. From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology. Physiol Rev. 2016;96(4):1593-659. [PDF]
Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1(7):1333-49. [PDF]
Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199-215. [PDF]
Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science. 2002;296(5568):678-82. [PDF]
Zlebnik NE, Cheer JF. Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation? Annu Rev Neurosci. 2016;39:1-17. [PDF]

ThreeD Capital Inc. $IDK.ca – Will 2020 Be The Year Of Enterprise #Bitcoin? #Ethereum $HIVE.ca $BLOC.ca $CODE.ca

Posted by AGORACOM-JC at 3:58 PM on Tuesday, December 17th, 2019

SPONSOR: ThreeD Capital Inc. (IDK:CSE) Led by legendary financier, Sheldon Inwentash, ThreeD is a Canadian-based venture capital firm that only invests in best of breed small-cap companies which are both defensible and mass scalable. More than just lip service, Inwentash has financed many of Canada’s biggest small-cap exits. Click Here For More Information.

Will 2020 Be The Year Of Enterprise Bitcoin?

  • Bitcoin is the most popular digital asset in the institutional trading world as it has the best trading options available, both spot and derivatives, proven track record with the longest history and availability of data.
  • This made some of the largest financial services institutions highly interested and in 2019 we saw the birth of several bitcoin products like Bakkt’s physically delivered bitcoin futures, Fidelity Digital Assets bitcoin custody solution and TD Ameritrade’s trading offerings.

Biser Dimitrov

It also the case for the large enterprises looking at blockchain as technology and wanting to innovate using easier payments over fast and secure transaction networks and processes built around smart contracts? Can they use the bitcoin blockchain as a foundation and place their middleware stack and end-user decentralized Web 3 and decentralized finance (DeFi) applications on top?

So far the majority of enterprise-focused blockchain development has been done on permissioned and private blockchain protocols like Hyperledger Fabric and R3’s Corda. This is mostly due to the fact that they offer sufficient privacy, scalability and transaction finality guarantees. Compared to them, development on top of the bitcoin blockchain was not seriously considered until recently when in May, Microsoft announced their permissionless, Decentralized Identifier (DID) network called ION running exclusively on top of the bitcoin blockchain. That triggered a shift in the sentiment that developers and enterprises should also consider bitcoin as a potential layer for enterprise blockchain development. For example, companies like Bitfury are already making significant progress with enterprise-tailored blockchain offerings like blockchain as a service (BaaS) using bitcoin as a base layer.

Let’s review how bitcoin stacks up as an enterprise-ready development platform. According to a recent Ernst & Young study among decision makers across the U.S., Europe and Asia, the major reasons to consider blockchain in general are:

· Preservation of data integrity – In this area bitcoin is the absolute winner as the most trusted and secure public blockchain. The bitcoin blockchain is currently secured by 97 quintillion hashes per second, or EH/s. Data integrity is priority number one for the maintainers of the bitcoin blockchain and they are very restrictive about any new feature that can introduce security bugs and potentially compromise the integrity of the protocol. The accuracy and consistency of the data can be easily observed and analyzed by simple blockchain explorers as well as by using surveillance tools like Elliptic, Elementus and Chainalysis.

· Ability to build new revenue/business models – Bitcoin currently has a $128 billion liquid market cap so building new models on top of it can unlock new significant revenue channels. Furthermore, the increased adoption of Layer 2 technology like the Lightning Network, which operate via channels and enable cheap and fast payments, will enable new business processes and ways to revenue.

· Increased operational efficiency – Since 2010, when certain opcodes were taken out of the core protocol, smart contracts were considered taboo in bitcoin. Lately, with the development of Blockstream’s Liquid and the new RSK framework, Schnorr signatures and Taproot will make smart contracts–like executions possible via sidechains.

Source: https://www.forbes.com/sites/biserdimitrov/2019/12/17/will-2020-be-the-year-of-enterprise-bitcoin/#402c169e3647

CardioComm Solutions $EKG.ca – #Mhealth Technologies Market Projected to Gain Significant Value $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 11:59 AM on Tuesday, December 17th, 2019

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

Mobile Health (MHealth) Technologies Market Projected to Gain Significant Value

By: trendsmarketresearch

  • The global mHealth market should reach $46.2 billion by 2021 from $13.2 billion in 2016 at a compound annual growth rate (CAGR) of 28.6%, from 2016 to 2021.

Report Scope:

This new report on mobile health will provide a brief description of the current status of the industry and recent developments. It presents the changing environment, in terms of new challenges and opportunities for app development, remote monitoring and networking medical data. The report analyzes the market trends, leading service providers, therapeutic markets and the most popular mHealth applications, in terms of downloads and revenues.

Report Includes:

– A global overview of the mobile health technology market.
– Analyses of global market trends, with data from 2014 and 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
– A presentation of the changing mobile health technology environment in terms of new challenges and rising opportunities.
– Information regarding market trends, leading service providers, therapy markets, and the most popular mHealth applications.
– Insight into the second generation of mHealth devices, projected regulatory patterns, and innovative devices and services to be launched in the near future.
– Company profiles of major players in the industries covered.

Report Summary

Mobile health (mHealth) is the use of mobile and wireless technologies to support healthcare systems and achieve healthcare objectives. Digital health solutions have the potential to improve the quality of healthcare, to democratize medical knowledge and provide healthcare to billions or people who have limited or no access to services. The provision of healthcare remains high on the economic and political agenda and continues to demand a huge share of gross domestic product (GDP) in industrialized countries, where an aging population and increase in the prevalence of chronic noncommunicable diseases (NCDs) remains a challenge.

mHealth can provide better and more consistence solutions within the global healthcare environment and will change the way services are provided in the future. Smart devices and wearable are empowering individuals to more effectively manage their care, raising awareness, providing continuous monitoring and disseminating of information to the patient and healthcare professionals; driving a more proactive, patient-centric healthcare system.

Source: https://statsflash.com/mobile-health-mhealth-technologies-market-projected-to-gain-significant-value-by-to-2021/743242/

Empower Clinics $CBDT.ca – As Smoke Clears From 2019, The US Cannabis Market Focuses On 2020 $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 12:02 PM on Monday, December 16th, 2019

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Platform generating $1.4M USD (9 months ending Sept. 30, 2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 6,000 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025

As Smoke Clears From 2019, The US Cannabis Market Focuses On 2020

  • The U.S. legal cannabis market is forecast to grow to $30 billion by 2025, as state markets quickly cannibalize demand from the illicit market, thereby achieving a key objective of legalization in undercutting the unregulated activities
  • Through the robust growth in currently legal markets, cannabis will likewise continue to be a significant generator of new jobs (from 258,437 in 2019, to a projected 743,196 in 2025 – an increase of 188%), and of tax revenues for the federal and state goverments ($1.41 billion in 2019, projecting to $4.06 billion in 2025)

By: New Frontier Data

While 2019 was a year marked by turbulence and reconsidered expectations in the legal cannabis industry, significant opportunities for growth and prosperity nevertheless await in 2020.

Despite strong consumer demand, challenges in operationalizing key markets – including Canada and California – coupled with slow progress toward U.S. federal legalization (among other reasons) have resulted in a slowdown in cannabis investments and dramatic contraction in value of the largest companies.Though the mysterious vaping crisis of EVALI (i.e., “e-cigarette or vaping, product use associated lung injuries”) threw a virtual wrench into a segment which had been projected to account for 29% of U.S. legal cannabis sales and $4.9 billion in 2019, other categories have seen strong sustained growth amid strong consumer demand.

The U.S. legal cannabis market is forecast to grow to $30 billion by 2025, as state markets quickly cannibalize demand from the illicit market, thereby achieving a key objective of legalization in undercutting the unregulated activities. Through the robust growth in currently legal markets, cannabis will likewise continue to be a significant generator of new jobs (from 258,437 in 2019, to a projected 743,196 in 2025 – an increase of 188%), and of tax revenues for the federal and state goverments ($1.41 billion in 2019, projecting to $4.06 billion in 2025).

Given the growth seen in Colorado’s successful program, a prosperous market is achievable if deftly managed, and critical growing pains are avoided. However, it takes years for the market’s economics to stabilize, a period during which efficiency, scale, and competition all increase dramatically. Even as Colorado’s legal market nears saturation, wholesale prices (which have already fallen by half) in the Rocky Mountain State are expected to continue to fall, driving further consolidation as less efficient and undifferentiated producers are displaced by high-performing operators.

Meantime, markets are opening in Illinois and Michigan, and Florida seems headed for an adult-use referendum in the nation’s third-most populous state, which approved medical use with 71% in favor in 2016. Almost all Americans now live in a market which has expanded to include access to either CBD, medical, or full adult-use purchases. And with more than a dozen other states likely to further expand legal cannabis access within the next two or three years, the delays in federal regulatory reform appear to be doing little to slow the public’s rising enthusiasm for legalization.

Innovation is driving development of new products. A far-flung range of cannabis-related technologies are emerging to attract new demographic groups and new opportunities through everything from Big Data business analytics to compliance testing, new extraction technologies, and the rise of smart consumption devices.

U.S. hemp saw a 459% increase in cultivation acreage from 2018 to 2019. Passage of the 2018 U.S. Farm Bill catalyzed the dramatic growth, though lack of the industry’s processing capacity coupled with supply-chain challenges to leave some early producers struggling to get harvests and products to market.

Here too, innovation and commercialization will play a transformative role, activating new applications that are in development, from bioplastics to construction materials. As the U.S. hemp industry matures, it will transition from being a seed, textile, and industrial product importer to a global exporter. Though the U.S. had lagged behind countries like Canada and France with hemp legislation, the 2018 Farm Bill cleared the way for the U.S. industry to accelerate and establish itself as a global exporting powerhouse led by hemp-derived CBD.

While the U.S. federal government through the Food and Drug Administration (FDA) and the U.S. Agriculture Department (USDA) offers more confusion than clarity about the legality of CBD products and use, domestic and international demand keeps expanding apace.

While the FDA promises guidance to be forthcoming, it is likelier that confusion will confound consumers for the foreseeable future, throughout 2020 and beyond until the long-term research studies which federal prohibition prevented for decades can finally be performed.

Heading into the new year, the convergent forces which characterized 2019’s turbulence are not yet resolved. However, as the irrational exuberance that has fueled much of the speculative investments in cannabis has been displaced by a more clear-eyed, long-term strategic approach, the companies that weather the storm will be keenly positioned to capitalize on the significant growth opportunities which legal cannabis will present globally in 2020.

Click Here to see 10 intriguing cannabis statistics from 2019

Source: https://www.benzinga.com/node/14993046

VIDEO: ZEN Graphene $ZEN.ca Recaps Successful 2019, Enters 2020 Strong $LLG.ca $FMS.ca $NGC.ca $CVE.ca $DNI.ca

Posted by AGORACOM-JC at 7:30 PM on Sunday, December 15th, 2019

This decade began with incredible hope for graphene as the miracle material that would change everything.

By 2015, hope gave way to indifference as graphene failed to live up to the smallest of expectations.

With the next decade just 15 days away, ZEN Graphene Solutions has reignited the great graphene hope with a string of great successes in 2019 that put commercialization within sight.

If you walked away from graphene years ago, you now owe it to yourself to watch this interview with ZEN CEO Francis Dube and find out why 2020 could mark the start of the graphene decade.